Manufacturing Sites

Expanding and Growing Our Global Presence

Minapharm has established six manufacturing sites, including two expansions in Cairo and Berlin that cater to the development and end-to-end manufacturing of advanced biologics’ therapies.

Minapharm Prime Facility

More than 150 Medicines from Small Molecules to Complex Bioengineered Products

Established in the early 90’s, Minapharm prime facility is headquartered in Cairo, Egypt. The fully automated factory relies on state-of-the-art machinery to deliver more than 150 lifesaving and life-enhancing medicines. These range from small molecules to extremely complex bioengineered products.

At the Minapharm prime facility, we manufacture our proprietary licensed products as well as generics and unique galenic formulations. We also produce line extensions in multiple dosage forms to accommodate a diverse array of needs.

Our facility complies with current Good Manufacturing Practice regulations (CGMPs), ISO standards, World Health Organization (WHO), and other international standards regulating the pharmaceutical industry.

Facility Highlights

  • Fully automated factory supported with the latest advanced machineries and manufacturing technologies.
  • Established in the early 90’s.
  • Headquartered in Cairo, Egypt over 12,400m2.
  • 1400+ qualified and well trained employees.
  • Broad portfolio of more than 150 life-saving and life-enhancing medicines ranging from small molecules to extremely complex bioengineered products.
  • Manufactures branded licensed products as well as first to launch generics, and unique galenic formulations, line extensions in all dosage forms serving diversified therapeutic areas.
  • Specialized in manufacturing unique dosage forms and potent drugs.
  • Complies with current Good Manufacturing Practice “cGMP”, ISO standards, World Health Organization “WHO” guidelines.
MiGenTra Egypt

Specialized in the Development and Manufacture of Therapeutic Proteins and Vaccines

MiGenTra Egypt is the first R&D and biopharmaceutical manufacturing facility in Egypt, Africa, and the Middle East. The facility specializes in the development and manufacture of therapeutic recombinant proteins and vaccines and is primarily focused on liver disease, thrombosis and haemostasis, infertility, oncology, and rheumatoid arthritis.

Facility Highlights

  • First biologics API manufacturing site in the MEA- operating since 2004
  • 100+ highly qualified bioprocess expert individuals (production and QC)
  • Egyptian-German hybrid culture
  • GMP-manufacturing license for manufacturing of recombinant proteins for yeast and mammalian cell lines
  • 1 x 500L stainless steel Bioreactor for yeast expression systems
  • 2 x 200L Single use Bioreactors for mammalian expression systems
ProBioGen AG

Internationally Renowned and Experienced CDMO and Technology Provider

Established more than 25 years ago, ProBioGen is a contract development and manufacturing organization (CDMO) and technology provider located in Berlin, Germany. The company specializes in the development and manufacture of complex therapeutic proteins. The facility and its expansion include state-of-the-art GMP production sites.

Facility Highlights

  • Minapharm's wholly owned Berlin-based subsidiary.
  • An internationally-renowned contract development and manufacturing organization (CDMO).
  • Founded 1994 as a spin-off from the Charité (one of the largest university hospitals in Europe).
  • Specialized in cell-line engineering and innovative proprietary technologies:
    • Protein cell line development
    • Candidate characterization and bioassays
    • Process yield optimization using Transposase technology
    • Enhancing protein therapeutic efficacy using advanced glycoengineering
    • Viral vector production cell lines and technologies
    • GMP manufacturing
  • More than 300 employees
MiGenTra GmbH

First Cell and Gene Therapy Facility in Africa and the Middle East

Established in 2022, Minapharm’s factory of the future is the first cell and gene therapy manufacturing facility in Africa and the Middle East. Located in Egypt, it specializes in the production of advanced therapies and medicinal products in the biotechnology sector. The facility complies with EMA standards and is equipped with tens of thousands of liter fermenters.

Facility Highlights

  • From drug substance API manufacturing to fill & finish, quality control, storage of starting materials and intermediates
  • 6 stories, 15,000m2
  • GMP compliant
  • Maximum total capacity: 40,000 Litre fermenters
  • Proteins, monoclonal antibodies, viral vectors and cell therapy
  • Planned headcount of 400+
  • Fully integrated IT systems: BMS, EMS, MES, LIMS, ERP
  • EU compliant design and EU-certification project ongoing
  • Acting as a biological API hub for the MEA region